Search the Newsreel

Bristol Myers Squibb Company $BMY Shares Sold by Empowered Funds LLC

Empowered Funds LLC significantly reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 38.0% during the first quarter, selling 210,880 shares and leaving them with 344,513 shares valued at over $20 million. Other institutional investors like Swiss RE Ltd., Darwin Wealth Management LLC, …

Bristol Myers Squibb Hopes to Boost Drug Trials with NVIDIA Supercomputer

Bristol Myers Squibb (BMS) is set to become the first life sciences company to acquire NVIDIA's latest generation supercomputer, the NVIDIA DGX SuperPOD with AIDGX Vera Rubin NVL72 systems. This move deepens a three-year partnership between the two companies, aiming to accelerate drug discovery …

Bristol Myers Squibb (BMY) Stock Still Looks Cheap After Fresh AI Drug Discovery News

Bristol Myers Squibb (BMY) has seen a 42.2% return over the past year, with a Discounted Cash Flow (DCF) model suggesting its intrinsic value is significantly higher than its current share price, implying it's undervalued by 48.1%. The company's expansion into AI-driven drug discovery …

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow

Bristol-Myers Squibb (BMY) is set to report its Q2 earnings this Thursday before market open. The company previously beat revenue expectations but slightly missed full-year EPS guidance. Analysts generally anticipate a 6.3% year-over-year revenue decline this quarter, while investor sentiment for the pharmaceutical sector …

New Iza-bren Approvals Underscore China's Rising Role In Bispecific ADCs

New approvals for Biokin’s Iza-bren, a first-in-class EGFRxHER3 bispecific ADC, for advanced nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma, highlight China's growing influence in this field. Biokin aims for global commercialization, leveraging its first-mover advantage and partnership with Bristol Myers Squibb. …

Lazard Asset Management LLC Raises Stake in Bristol Myers Squibb Company $BMY

Lazard Asset Management LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 23.7% in the first quarter, now owning 1,924,036 shares valued at $116.69 million. Other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC also significantly …

Bristol-Myers Squibb stock rating held at Market Perform by Raymond James

Raymond James reiterated a Market Perform rating on Bristol-Myers Squibb (NYSE:BMY), stating that recent ZEPHYR trial data for ML-007C-MA does not pose a risk to Cobenfy and confirms its strong position in schizophrenia treatment. The firm believes Cobenfy has a significant commercial and clinical …

Bristol Myers Squibb (NYSE:BMY) Reaches New 52-Week High - Should You Buy?

Bristol Myers Squibb (NYSE:BMY) recently hit a new 52-week high of $63.24, trading around $63.07, and has a market capitalization of approximately $128.1 billion. Analyst sentiment is mixed, with 8 buys, 10 holds, and 1 sell rating, and an average price target of $61.25, …

Bristol Myers Squibb launches Relopduo, its fixed-dose combination for skin cancer, in India

Bristol Myers Squibb (BMS) has launched Relopduo, a fixed-dose combination for unresectable or metastatic melanoma, in India. This drug, which combines nivolumab and relatlimab, is the first FDA-approved FDC of two immune checkpoint inhibitors. Priced at ₹2,99,900 per vial, it offers a new treatment …

Theo Ai Strengthens Governance With Appointment of Former Bristol Myers Squibb GC to Board

Theo Ai has appointed Sandra Leung, former Executive Vice President and General Counsel of Bristol Myers Squibb, to its Board of Directors, enhancing the company's governance and strategic direction. Leung's extensive experience in litigation, corporate governance, and risk management will help tailor Theo Ai's …

Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board

Theo Ai has appointed Sandra Leung, former EVP and General Counsel of Bristol Myers Squibb, to its board of directors. Leung previously served on Theo Ai’s General Counsel Advisory Board and brings over 30 years of corporate legal experience, including expertise in litigation risk …

BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge By Investing.com

BMO Capital has reiterated its Market Perform rating and $60.00 price target for Bristol-Myers Squibb (NYSE: BMY), citing the competitive advantage of its schizophrenia drug, Cobenfy. This follows a failed Phase 2 trial for a competing drug, ML-007C-MA, which did not meet statistical significance. …

Bristol-Myers Squibb stock hits 52-week high at 62.89 USD

Bristol-Myers Squibb (BMY) stock recently hit a new 52-week high of $62.89, trading at $62.95 with a market capitalization of $127.94 billion. The company has maintained dividend payments for 56 consecutive years, currently yielding 4.06%. This milestone follows the FDA's acceptance of their New …

Bristol-Myers Squibb Company Revenue Breakdown – HAM:BRM

Bristol-Myers Squibb Company (HAM:BRM) generated €41.03 billion in revenue last year, primarily from its Innovative Medicines segment. This marks a decrease from the previous year's €46.66 billion. The United States was the largest contributor to revenue, accounting for €28.33 billion.

Bristol-Myers Squibb Company Celegne Contingent Value Revenue Breakdown – BOATS:CELG/R

This article provides a brief overview of Bristol-Myers Squibb Company's Celgene Contingent Value financials, specifically focusing on its revenue breakdown for the Innovative Medicines segment and geographical contributions. Last year, the company generated $48.19 billion USD from Innovative Medicines, with the largest portion, $33.28 …

Bristol-Myers Squibb Expands Pipeline With New First-in-Human Trial for BMS-986533

Bristol-Myers Squibb (BMY) has initiated a first-in-human Phase 1 trial for BMS-986533, an oral drug, to evaluate its safety, pharmacokinetics, and dosing in healthy volunteers. This randomized, double-blind, placebo-controlled study includes multiple dosing schemes and assesses interactions with common medications. The trial, which began …

Oak Associates Ltd. OH Acquires New Position in Bristol Myers Squibb Company $BMY

Oak Associates Ltd. OH has acquired a new position in Bristol Myers Squibb Company, purchasing 131,790 shares valued at approximately $8.0 million during the first quarter. Bristol Myers Squibb reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and announced a …

Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co.

Sei Investments Co. increased its stake in Bristol Myers Squibb (NYSE:BMY) by 8.2% in the first quarter, bringing its total holdings to over 2.19 million shares valued at $133 million. Several other institutional investors also adjusted their positions in BMY. Analysts have a mixed …

BMY|Bristol-Myers Squibb Co|Price:63.745|Chg%:-1.095

Bristol Myers Squibb Takes Drugmaker Week Rank at 92.6% of Its Yearly Range

BMY added 5.5% in the latest week and led its US Drug Manufacturers - General group, but Sharemaestro Market Dynamics have not fully confirmed the move.

Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts

Bristol Myers Squibb (BMY) saw a 1.05% gain, closing at $61.40, while the broader market declined. The stock has increased by 10.47% over the past month, outperforming both the Medical sector and the S&P 500. Analysts anticipate an 8.9% year-over-year earnings growth for its …

DOL Brief Sides With Bristol-Myers in PRT Appeal

The U.S. Department of Labor filed an amicus brief supporting Bristol-Myers Squibb in an appeal, arguing that retirees lack Article III standing to sue over pension risk transfers if they continue to receive full benefits. This action, along with a similar brief for Lockheed …

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains

Bristol Myers Squibb Co. (BMY) shares rose by 1.23% on Thursday, closing at $61.51, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. The stock, however, still underperformed compared to some competitors and ended 2.19% below its …

Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

Bristol Myers Squibb (BMY) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2026, with Wall Street anticipating $1.59 EPS on $11.67 billion in revenue. The company has a Zacks Earnings ESP of +0.51% and a …

DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal

The U.S. Department of Labor has filed an amicus brief supporting Bristol-Myers Squibb in a pension risk transfer (PRT) appeal, joining business groups, insurers, and states. They argue that retirees lack Article III standing as they still receive full benefits and that allowing such …

Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued?

Bristol-Myers Squibb (BMY) has gained momentum following FDA acceptance of its New Drug Application for mezigdomide and an AI collaboration with Nvidia for drug discovery. The company is currently considered 3.2% undervalued with a fair value of $62.96, despite existing risks related to patent …

Bristol Myers Squibb (BMY) Opens 427,000 Square Foot San Diego Hub For AI Drug Discovery

Bristol Myers Squibb (BMY) has opened a significant 427,000 square foot R&D hub in San Diego, integrating NVIDIA-powered AI infrastructure to accelerate drug discovery. This initiative aims to enhance the speed and efficiency of its oncology, cardiovascular, and immunology programs, potentially offsetting patent expiries …

WashU announces new academic-industry collaboration with Bristol Myers Squibb

Washington University in St. Louis and Bristol Myers Squibb have initiated a multiyear collaboration to foster scientific exchange and advance drug development in neuroscience. This partnership will provide WashU medical and research trainees with opportunities to work alongside Bristol Myers Squibb scientists and will …

Lobbying Update: $3,160,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed

A recent lobbying disclosure reveals that Bristol-Myers Squibb Company (BMY) reported $3,160,000 in lobbying expenditures for Q2 2026, addressing issues such as drug pricing, intellectual property reform, and the Inflation Reduction Act. The article also details recent congressional stock trading, insider transactions, hedge fund …

Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Bristol Myers Squibb plans to construct "the most powerful AI factory in life sciences" with Nvidia's assistance, marking its expanded collaboration to enhance AI capabilities for complex pharmaceutical problems. Meanwhile, Samsung Biologics is moving to acquire PolyPeptide Group for approximately $1.8 billion, a strategic …

Bristol Myers Squibb is deploying NVIDIA's most powerful AI computing system to speed drug discovery

Bristol Myers Squibb is expanding its computing infrastructure by deploying a second NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems, which provides ten times greater performance per megawatt and will significantly accelerate drug discovery. This investment extends an existing three-year partnership with …

Bristol Myers Squibb Expands Partnership with Nvidia | PharmExec

Bristol Myers Squibb is significantly expanding its AI computing infrastructure through a partnership with Nvidia, aiming to create the most powerful AI factory in life sciences. This initiative will leverage Nvidia DGX SuperPOD systems to accelerate research across multiple therapeutic areas, with AI agents …

Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory

Bristol Myers Squibb (BMS) is significantly expanding its collaboration with Nvidia by deploying DGX SuperPOD with Vera Rubin NVL72 systems, creating what it claims is the most powerful AI computing infrastructure in life sciences. This aims to accelerate drug discovery and development across various …

Bristol Myers boosts AI capacity with expanded use of Nvidia systems

Bristol Myers Squibb (BMY) has expanded its artificial intelligence capabilities by implementing Nvidia's (NVDA) DGX SuperPOD with DGX Vera Rubin NVL72 systems. This move is expected to enhance the drugmaker's operations, leveraging Nvidia's supercomputing infrastructure.

Bristol Myers Squibb Deploys NVIDIA Vera Rubin AI Factory To Accelerate Drug Discovery

Bristol Myers Squibb is expanding its use of artificial intelligence for drug discovery by deploying a second NVIDIA DGX SuperPOD, an "AI factory" built on NVIDIA DGX Vera Rubin NVL72 systems. This initiative aims to provide all scientists with access to a unified AI …

Bristol Partners With Nvidia on AI Factory for Drug Development

Bristol Myers Squibb Co. is expanding its partnership with Nvidia Corp. to enhance the computing power of its AI factory, aiming to accelerate the development of new medicines. This collaboration is part of a broader trend where the chipmaker partners with the pharma industry …